Expression of claudin‐18.2 in cholangiocarcinoma: a comprehensive immunohistochemical analysis from a German tertiary centre
The present study suggests that a subset of patients with CCA exhibited a marked expression of CLDN18.2. These findings underline the need to perform a clinical study evaluating the efficacy of anti-CLDN18.2 therapy in patients suffering from CCA.
Authors
- Henning Reis (ORCID: https://orcid.org/0000-0003-1373-5295)
- Fabian Finkelmeier (ORCID: https://orcid.org/0000-0001-8559-9910)
- Peter Johannes Wild (ORCID: https://orcid.org/0000-0002-1017-3744)
- Wolf O. Bechstein (ORCID: https://orcid.org/0000-0002-3267-8145)
- Stefan Zeuzem (ORCID: https://orcid.org/0000-0002-0845-6833)
- Katrin Bankov (ORCID: https://orcid.org/0009-0005-4033-4966)
- Dirk Walter (ORCID: https://orcid.org/0000-0003-2309-9624)
- Maximilian N. Kinzler (ORCID: https://orcid.org/0000-0003-2378-1455)
- Nada Abedin (ORCID: https://orcid.org/0000-0002-3952-9855)
- Steffen Gretser (ORCID: https://orcid.org/0000-0002-4875-3808)
- Falko Schulze
Institutions
- Goethe University Frankfurt (DE)
- Frankfurt Institute for Advanced Studies (DE)
- Humboldt-Universität zu Berlin (DE)
- University Hospital Frankfurt (DE)
- Frankfurt Cancer Institute (DE)
- Freie Universität Berlin (DE)
- Charité - Universitätsmedizin Berlin (DE)
Publication Details
- Journal
- Histopathology
- Published
- 2024-12-27
- DOI
- https://doi.org/10.1111/his.15407
- Citations
- 6
- Primary Topic
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 3.44